Literature DB >> 19853487

Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis.

Satomi Koyama1, Laura J Cobb, Hemal H Mehta, Navindra P Seeram, David Heber, Allan J Pantuck, Pinchas Cohen.   

Abstract

The IGF axis is critical for the regulation of apoptosis in many human cancer cell lines. Recently, potent anti-tumorigenic effects of pomegranate juice and extracts have been reported. Consequently, pomegranate has potential not only as a treatment but also as a preventative measure against certain types of cancer, including prostate. In this study, we investigated the relationship between pomegranate-induced apoptosis in human prostate cancer cells and the IGF/IGFBP system. Treatment of LAPC4 prostate cancer cells with 10microg/ml POMx, a highly potent pomegranate extract prepared from skin and arils minus seeds and standardized to ellagitannin content (37% punicalagins by HPLC), resulted in inhibition of cell proliferation and induction of apoptosis. Interestingly, co-treatment with POMx and IGFBP-3 revealed synergistic stimulation of apoptosis and additive inhibition of cell growth. Western blot analysis revealed that treatment with POMx or POMx/IGFBP-3 combination resulted in increased JNK phosphorylation, and decreased Akt and mTOR activation, consistent with a growth inhibitory, pro-apoptotic function. We also investigated the relationship between IGF-1 and pomegranate-induced apoptosis in 22RV1 prostate cancer cells. Co-treatment with 100ng/ml IGF-1 completely blocked apoptosis induction by POMx. In contrast, IGF-I failed to inhibit POMx-induced apoptosis in R(-) cells, suggesting the importance of IGF-IR. POMx-treatment decreased Igf1 mRNA expression in a dose-dependent manner indicating that its actions also involve tumor-specific suppression of IGF-1. These studies revealed novel interactions between the IGF system and pomegranate-induced apoptosis. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19853487      PMCID: PMC2815223          DOI: 10.1016/j.ghir.2009.09.003

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  39 in total

1.  Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing.

Authors:  M I Gil; F A Tomás-Barberán; B Hess-Pierce; D M Holcroft; A A Kader
Journal:  J Agric Food Chem       Date:  2000-10       Impact factor: 5.279

Review 2.  Cellular actions of the insulin-like growth factor binding proteins.

Authors:  Sue M Firth; Robert C Baxter
Journal:  Endocr Rev       Date:  2002-12       Impact factor: 19.871

Review 3.  Cancer chemoprevention with dietary phytochemicals.

Authors:  Young-Joon Surh
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

4.  Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer.

Authors:  Nam Deuk Kim; Rajendra Mehta; Weiping Yu; Ishak Neeman; Talia Livney; Akiva Amichay; Donald Poirier; Paul Nicholls; Andrew Kirby; Wenguo Jiang; Robert Mansel; Cheppail Ramachandran; Thangaiyan Rabi; Boris Kaplan; Ephraim Lansky
Journal:  Breast Cancer Res Treat       Date:  2002-02       Impact factor: 4.872

5.  Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice.

Authors:  M Aviram; L Dornfeld; M Rosenblat; N Volkova; M Kaplan; R Coleman; T Hayek; D Presser; B Fuhrman
Journal:  Am J Clin Nutr       Date:  2000-05       Impact factor: 7.045

6.  Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis.

Authors:  M Kaplan; T Hayek; A Raz; R Coleman; L Dornfeld; J Vaya; M Aviram
Journal:  J Nutr       Date:  2001-08       Impact factor: 4.798

7.  Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice.

Authors:  Begoña Cerdá; Rafael Llorach; José J Cerón; Juan Carlos Espín; Francisco A Tomás-Barberán
Journal:  Eur J Nutr       Date:  2003-01       Impact factor: 5.614

8.  Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells.

Authors:  Martin Albrecht; Wenguo Jiang; James Kumi-Diaka; Ephraim P Lansky; Lyndon M Gommersall; Amit Patel; Robert E Mansel; Ishak Neeman; Albert A Geldof; Moray J Campbell
Journal:  J Med Food       Date:  2004       Impact factor: 2.786

9.  Repeated oral administration of high doses of the pomegranate ellagitannin punicalagin to rats for 37 days is not toxic.

Authors:  Begoña Cerdá; José J Cerón; Francisco A Tomás-Barberán; Juan Carlos Espín
Journal:  J Agric Food Chem       Date:  2003-05-21       Impact factor: 5.279

Review 10.  Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule.

Authors:  O Ali; P Cohen; K-W Lee
Journal:  Horm Metab Res       Date:  2003 Nov-Dec       Impact factor: 2.936

View more
  25 in total

1.  Apoptotic effects of non-edible parts of Punica granatum on human multiple myeloma cells.

Authors:  Yağmur Kiraz; Vidushi S Neergheen-Bhujun; Nawraj Rummun; Yusuf Baran
Journal:  Tumour Biol       Date:  2015-08-29

Review 2.  Diet and lifestyle considerations for patients with prostate cancer.

Authors:  Kyle B Zuniga; June M Chan; Charles J Ryan; Stacey A Kenfield
Journal:  Urol Oncol       Date:  2019-07-18       Impact factor: 3.498

3.  A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.

Authors:  C J Paller; X Ye; P J Wozniak; B K Gillespie; P R Sieber; R H Greengold; B R Stockton; B L Hertzman; M D Efros; R P Roper; H R Liker; M A Carducci
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-06-12       Impact factor: 5.554

4.  Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model.

Authors:  Vaqar Mustafa Adhami; Imtiaz Ahmad Siddiqui; Deeba N Syed; Rahul Kumar Lall; Hasan Mukhtar
Journal:  Carcinogenesis       Date:  2011-12-22       Impact factor: 4.944

5.  Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease.

Authors:  Victor Tapias; Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Aging       Date:  2013-10-21       Impact factor: 4.673

6.  A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.

Authors:  A J Pantuck; C A Pettaway; R Dreicer; J Corman; A Katz; A Ho; W Aronson; W Clark; G Simmons; D Heber
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-07-14       Impact factor: 5.554

Review 7.  Pomegranate extracts and cancer prevention: molecular and cellular activities.

Authors:  Deeba N Syed; Jean-Christopher Chamcheu; Vaqar M Adhami; Hasan Mukhtar
Journal:  Anticancer Agents Med Chem       Date:  2013-10       Impact factor: 2.505

8.  Induction of reactive oxygen species generation inhibits epithelial-mesenchymal transition and promotes growth arrest in prostate cancer cells.

Authors:  Trinath P Das; Suman Suman; Chendil Damodaran
Journal:  Mol Carcinog       Date:  2013-03-08       Impact factor: 4.784

9.  Improving active and passive avoidance memories deficits due to permanent cerebral ischemia by pomegranate seed extract in female rats.

Authors:  Alireza Sarkaki; Moslem Rezaiei; Mohammadkazem Gharib Naseri; Maryam Rafieirad
Journal:  Malays J Med Sci       Date:  2013-03

10.  A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy.

Authors:  Stephen J Freedland; Michael Carducci; Nils Kroeger; Alan Partin; Jian-Yu Rao; Yusheng Jin; Susan Kerkoutian; Hong Wu; Yunfeng Li; Patricia Creel; Kelly Mundy; Robin Gurganus; Helen Fedor; Serina A King; Yanjun Zhang; David Heber; Allan J Pantuck
Journal:  Cancer Prev Res (Phila)       Date:  2013-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.